Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay.
Araujo and Lanthier explain how the Toronto-based company's results suggest that MSP-1014 induces a “similar perceptual state to psilocybin, further confirming the viability of MSP-1014 as a therapeutic analog of first-generation psilocybin” as the company advances MSP-1014 into the clinic.